JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2015, 64(3):72-78 | DOI: 10.36290/csf.2015.020

The quality of life of patients suffering from the osteoporosis

Lucia Masaryková1,*, Magdaléna Fulmeková1,2, Ľubica Lehocká1, Tomáš Ďurdík1
1 Univerzita Komenského, Farmaceutická fakulta, Katedra organizácie a riadenia farmácie, Bratislava, SR
2 Univerzitná lekáreň FaF UK, Bratislava, SR

Osteoporosis (OP) is a systemic skeletal disease characterized by an imbalance of bone remodelling process due to the prevalence of osteoresorption over osteosynthesis. As a result of these changes, the decrease in bone mass and density occur followed by an increase in fracture risk1). Its clinical manifestation is initially asymptomatic but in the course of time it is quite the contrary - really severe (bone pain, movement disorders, fractures) with a lot of further adverse consequences, including death2). The presented study deals with the impact of osteoporosis and its consequences on the quality of life of patients. The research is focused on patients diagnosed with or treated for osteoporosis that is to say by non-uniform etiology. By questioning of the sample of 128 patients evaluating various dimensions of the patient's quality of life (physical condition, mental state, and social status, overall satisfaction with life and health state) and tracking patients' satisfaction with the therapy as well. By analysing the results, we found that osteoporosis affects the quality of life, especially physical state of health because up to 31.25% of patients say that they have suffered from every day's backaches. It affects social life in the member of 7.81% patients, and 28.13% patients say that biggest problem with osteoporosis is the loss of free movement and possible fracture.

Keywords: osteoporosis; quality of life; pharmacotherapy; questionnaire survey; fractures

Received: May 15, 2015; Accepted: June 1, 2015; Published: March 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masaryková L, Fulmeková M, Lehocká Ľ, Ďurdík T. The quality of life of patients suffering from the osteoporosis. Čes. slov. farm. 2015;64(3):72-78. doi: 10.36290/csf.2015.020.
Download citation

References

  1. Šteňová E., Šteňo B., Baqi L. Možnosti prevencie a liečby primárnej osteoporózy v ambulancii lekára prvého kontaktu. Via pract. 2008; 5(1), 34-38.
  2. Dusilová Sulková S. Nezastupitelná úloha vitaminu D v prevenci a léčbě osteoporózy. Prakt. lékáren. 2011; 7(2), 58-61.
  3. Consensus Development Conference Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94(6), 646-650.
  4. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843: 1-129
  5. Kanis J. A., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteopor. Int. 2008; 19(7), 1103-1104. Go to original source...
  6. Nguyen T., Sambrook P., Kelly P., Jones G., Lord S., Freund J., Eisman J. Prediction of osteoporotic fractures by postural in stability and bone density. BMJ 1993; 307(6912), 1111-1115. Go to original source... Go to PubMed...
  7. Čierny D., Killinger Z., Payer J. Farmakologická liečba osteoporózy. Via pract. 2008; 5(11), 462-464.
  8. Švehlíková L., Heretik ml. A. Kvalita života - o čom to hovoríme?. Psychiatria - psychoterapia - psychosomatika 2008; 15(3), 194-198.
  9. Hnilicová H., Bencko V. Kvalita života - vymezení pojmu a jeho význam pro medicínu a zdravotnictví. Prakt. Lék. 2005; 85(11), 656-660.
  10. Virág Ľ. Používanie liekov a kvalita života pacientov. Farmaceutická fakulta UK v Bratislave, prednáška.
  11. Tesař T., et al. Farmakoekonomika a hodnotenie kvality života pacientov. Via pract. 2008; 5(7/8), 332.
  12. Jenšovský J. Prevence osteoporózy. Interní medicína 2010; 12(3), 163-166.
  13. Masunari N., Fujiwara S. Impact factors of osteoporosis on health-related quality of life. In: Health-Related Quality of Life 2009; 1-30.
  14. Lips P., van Schoor N. M. Quality of life in patients with osteoporosis. Osteoporos. Int. 2005; 16(5), 447-455. Go to original source... Go to PubMed...
  15. Hopman W. M., et al. Prospectively measured 10-year changes in health-related quality of life and comparison with cross-sectional estimates in a population - based cohort of adult women and men. Quality of Life Research 2014. Go to original source...
  16. Azimi P., Shahzadi S., Azhari S., Montazeri A. An outcome measure of functionality and quality of life in Iranian women with osteoporotic vertebral fractures: a validation study of the QUALEFFO-41. J Orthopaedic Science 2014; 19(6), 860-867. Go to original source... Go to PubMed...
  17. Tomková S., Beličáková Z. Osteoporóza u mužov. Via pract. 2009; 6(9), 350-352.
  18. Palacios S., Neyro J. L., Fernández De Cabo S., Chaves J., Rejas J. Impact of osteoporosis and bone fracture on health-related quality of life in postmenopausal women. Climacteric 2014; 17(1), 60-70. Go to original source... Go to PubMed...
  19. Darbà J., et al. Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: A burden of illness study Global health. BMC Public Health 2015; 15(1); Article number 324. Go to original source... Go to PubMed...
  20. Johnell O., Kanis J. Epidemiology of osteoporotic fractures. Osteoporos. Int. 2005; 16 S3-S7. Go to original source... Go to PubMed...
  21. Špániková B. Onkologický ústav sv. Alžbety, Heydukova 10, Bratislava. Terapia osteoporózy. Prednáška. Kurz NEOX Academy: Osteológia pre monitorov klinických štúdií, Bratislava, 24. 11. 2010.
  22. Tomková S., et al. Therapeutic adherence to osteoporosis treatment. International Journal of Clinical Pharmacology and Therapeutics 2014; 52(8), 663-668. Go to original source... Go to PubMed...
  23. Rossini M., et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos. Int. 2006; 17(6), 914-992. Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.